Clinical trial
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
NCT00171769 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00171769 |
|---|---|
| Title | Atrial Fibrillation Feasibility Certoparin Trial - AFFECT |
| Official title | An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Persistent Nonvalvular Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | Certoparin |
| Enrollment | 200 |
| Start date | Apr 1, 2005 |
| Primary completion | Aug 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Feb 23, 2017 |
| Countries | Germany, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: